Clinical Trials Browser

Phase 1 × Small Cell Lung Carcinoma × PM 01183 × Clear all

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT01831089 2020-04-10

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Phase 1 Completed

69 enrolled 17 charts

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma